Management of osteoporosis with PTH: Treatment and prescription patterns in Europe

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 263-270

  Hosking, David ^a   Alonso, Carlos Gómez ^b   Brandi, Maria Luisa ^c  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Department of Clinical Physiopathology ^*  (Italy)

Author keywords

Fracture prevention; Osteoporosis; Postmenopausal; PTH; Reimbursement

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE;

BONE DENSITY; BONE FRAGILITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EUROPE; FRAGILITY FRACTURE; HEALTH CARE COST; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INCIDENCE; LUMBAR SPINE; MONOTHERAPY; MORTALITY; PATIENT COMPLIANCE; PELVIS FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; REIMBURSEMENT; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; SPINE FRACTURE; TRABECULAR BONE; TREATMENT INDICATION; VERTEBRA FRACTURE; WRIST FRACTURE; FRACTURE; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW;

BONE DENSITY; EUROPE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; POSTMENOPAUSE;

EID: 64249155269     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802645461     Document Type: Short Survey

References (63)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541 (Pubitemid 26411651)
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. J AmMed Assoc 1998;280:2077-2082
3. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91 (Pubitemid 30099515)
4. Whitfield JF. Growing Bone, 2nd edn. Austin, TX: Landes Bioscience, 2007
5. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703 (Pubitemid 41127277)
6. Hodsman AB, Hanley DA, Watson PH, et al. Parathyroid Hormone. San Diego: Academic Press, 2002
7. Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932;16:547
8. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-4612
9. Tam CS, Heersche JN, Murray TM, et al. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982;110:506-512 (Pubitemid 12162946)
10. Khosla S. The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055
11. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of Parathyroid Hormone, Alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-1226 (Pubitemid 37152031)
12. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-339
13. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-1441
14. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-5220
15. Roux C, Illera-Martín O, Clausen J. Efficacy of PTH(1-84) on vertebral and non-vertebral fractures in postmenopausal women with a high risk of vertebral fractures. Calcif Tissue Int 2007;80(Suppl. 1):S48
16. Black DM, Greenspan SL, Ensrud KE, et al. The effects of Parathyroid Hormone and Alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349:1207-1215 (Pubitemid 37152030)
17. Black DM, Bilezikian JP, Ensrud K, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New Engl J Med 2005;353:555-565
18. Felsenberg D, Delmas P, Hosking D, et al. Sequential treatment with full-length parathyroid hormone PTH (1-84) of postmenopausal women with primary osteoporosis. Calcif Tissue Int 2007;80:S126
19. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporosis Int 2000;11:669-674 (Pubitemid 30786246)
20. Melton III LJ, Atkinson EJ, O'Connor MK, et al. Bone density and fracture risk in men. J Bone Miner Res 1998; 13:1915-1923 (Pubitemid 28535849)
21. Melton III LJ, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-1010
22. Dennison E, Cole Z, Cooper C. Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol 2005;17:456-461 (Pubitemid 41058406)
23. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-1018 (Pubitemid 26200053)
24. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-474
25. EPOS Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002;17:716-724 (Pubitemid 34246648)
26. Leidig-Bruckner G, Limberg B, Felsenberg D, et al. Sex difference in the validity of vertebral deformities as an index of prevalent vertebral osteoporotic fractures: a population survey of older men and women. Osteoporos Int 2000;11:102-119 (Pubitemid 30168795)
27. Naves M, Diaz-Lopez JB, Gomez C, et al. Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50. Osteoporos Int 2005;16:2013-2017 (Pubitemid 41790921)
28. McCloskey EV, Spector TD, Eyres KS, et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporosis Int 1993;3:138-147 (Pubitemid 23125375)
29. HAS. Commision de la transparence. Avis, 05 Juillet 2006
30. Adachi JD, Ioannidis G, Olszynski WP, et al. The impact of incident vertebral and nonvertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord 2002;3:11 (Pubitemid 38994415)
31. Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporosis Int 1999;9:508-515 (Pubitemid 29348566)
32. Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychological and social outcomes. Rheum Dis Clin North Am 2001;27:255
33. Robbins J, Hirsch C, Whitmer R, et al. The association of bone mineral density and depression in an older population. J Am Geriatr Soc 2001;49:732-736 (Pubitemid 32652465)
34. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fracture and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:821-828
35. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. J Am Med Assoc 2001;285:320-323 (Pubitemid 32095035)
36. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739 (Pubitemid 30174026)
37. Ismail AA, Cockerill W, Cooper C, et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study Osteoporosis Int 2001;12:85-90
38. Cauley JA, Hochberg MC, Lui L-Y, et al. Long-term risk of incident vertebral fractures. J Am Med Assoc 2007;298:2761-2767 (Pubitemid 350294299)
39. Donaldson LJ, Cook A, Thomson RG. Incidence of fractures in a geographically defined population. J Epidemiol Community Health 1990;44:241-245 (Pubitemid 20327430)
40. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles' or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-2448
41. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. Br Med J 1993;307:1248-1250 (Pubitemid 23330506)
42. Magaziner J, Simonsick EM, Kashner TM, et al. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 1990;45:M101-M7 (Pubitemid 20171157)
43. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int 2005;16:229-238 (Pubitemid 40379422)
44. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-1112 (Pubitemid 38668990)
45. Feldstein AC, Nichols GA, Elmer PJ, et al. Older women with fractures: patients falling through the cracks of guideline recommended osteoporosis screening and treatment. J Bone Joint Surg Am 2003;85:A2294-302 (Pubitemid 37499637)
46. Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am 2000;82:1063-1070
47. Harrington JT, Broy SB, Derosa AM, et al. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum 2002;47:651-654
48. Kamel HK, Hussain MS, Tariq S, et al. Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Am J Med 2000;109:326-328
49. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004;180:S18-22 (Pubitemid 38313000)
50. Dreinhöfer KE, Féron JM, Herrera A, et al. Orthopaedic surgeons and fragility fractures. A survey by the Bone and Joint Decade and the International Osteoporosis foundation. J Bone Joint Surg 2004;86:958-961
51. Endres HG, Dasch B, Maier C, et al. Diagnosis and treatment of osteoporosis in postmenopausal women with distal radius fracture in Germany. Curr Med Res Opin 2007;23:2171-2181 (Pubitemid 350246603)
52. The European Union Osteoporosis Consultation Panel. Osteoporosis in the European Community: Action Plan. Brussels: European Commission, 2003
53. Torgerson DJ, Dolan P. Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 1998;57:378-379 (Pubitemid 28378316)
54. Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment. The ICARO study. J Bone Miner Res 2006;21:1565-1570 (Pubitemid 44484601)
55. Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 2006;368:973-974 (Pubitemid 44353676)
56. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-1652 (Pubitemid 44477625)
57. Bocuzzi SJ, Folz SH, Omar MA, et al. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporosis Int 2005;16(Suppl. 3):OC10
58. Cramer JA, Monkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-1460 (Pubitemid 41368578)
59. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008 (Pubitemid 40064656)
60. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-928 (Pubitemid 44498580)
61. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022 (Pubitemid 44175011)
62. Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporosis Int 2006;17:1626-1629 (Pubitemid 44477622)
63. Saag K, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid induced osteoporosis. New Engl J Med 2007;357:2028-2039 (Pubitemid 350106710)